• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Isosorbide dinitrate in plasma and dialysate during haemodialysis.

作者信息

Bauer H, Laufen H, Franz H E

出版信息

Eur J Clin Pharmacol. 1986;30(2):187-90. doi: 10.1007/BF00614300.

DOI:10.1007/BF00614300
PMID:3709643
Abstract

In 10 patients with end stage renal disease on regular haemodialysis the plasma concentrations and dialyzer clearance of isosorbide dinitrate (ISDN) were determined after an oral dose of a retarded release formulation of 60 mg ISDN. The maximal plasma concentration of ISDN 2-7 h after oral administration was higher (14 ng/ml) than has been reported in healthy volunteers. The haemodialyzer clearance of ISDN was 92.4 ml/min at a blood flow of 200 ml/min and dialysate flow of 500 ml/min. During a 5-h haemodialysis an average of 0.3 mg ISDN was removed from the patient's circulation, representing about 0.5% of the administered dose and about 3% of the available drug in the circulation. No influence of haemodialysis on the plasma level of ISDN was found.

摘要

相似文献

1
Isosorbide dinitrate in plasma and dialysate during haemodialysis.
Eur J Clin Pharmacol. 1986;30(2):187-90. doi: 10.1007/BF00614300.
2
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.不同剂型的硝酸异山梨酯和肼屈嗪以及硝酸异山梨酯/肼屈嗪固定剂量复方之间缺乏生物等效性:V-HeFT悖论。
Clin Pharmacokinet. 2007;46(10):885-95. doi: 10.2165/00003088-200746100-00006.
3
[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Arzneimittelforschung. 1987 Nov;37(11):1301-3.
4
Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood.硝酸异山梨酯在人血中孵育后代谢的性别差异。
Biochem Pharmacol. 1983 Dec 15;32(24):3729-34. doi: 10.1016/0006-2952(83)90142-9.
5
Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.静脉注射和口服后异山梨醇二硝酸酯的药代动力学及代谢
Eur J Clin Pharmacol. 1985;27(6):637-44. doi: 10.1007/BF00547041.
6
Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.硝酸酯类耐受性:持续口服硝酸异山梨酯后静脉注射硝酸异山梨酯的血流动力学效应
Clin Ther. 1990 Jan-Feb;12(1):31-43.
7
Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.硝酸异山梨酯经皮喷雾剂的生物利用度和代谢
Arzneimittelforschung. 1992 Jul;42(7):931-5.
8
[Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate].[手术患者静脉输注过程中硝酸异山梨酯及其代谢产物的血浆水平——硝酸异山梨酯术前给药的影响]
Masui. 1993 Feb;42(2):225-32.
9
Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.
Biopharm Drug Dispos. 1992 Jul;13(5):357-67. doi: 10.1002/bdd.2510130507.
10
Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Isr J Med Sci. 1979 May;15(5):448-50.

引用本文的文献

1
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
2
Clinical pharmacokinetics of nitrates.硝酸盐的临床药代动力学
Cardiovasc Drugs Ther. 1994 Oct;8(5):693-9. doi: 10.1007/BF00877116.
3
Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.
Klin Wochenschr. 1989 Mar 15;67(6):342-8. doi: 10.1007/BF01741389.

本文引用的文献

1
[Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].
Dtsch Med Wochenschr. 1980 Oct 3;105(40):1379-83. doi: 10.1055/s-2008-1070875.
2
Fate of isosorbide dinitrate and mononitrates in patients with renal failure.硝酸异山梨酯及其单硝酸酯在肾衰竭患者体内的转归
Eur J Clin Pharmacol. 1981;21(1):73-6. doi: 10.1007/BF00609591.
3
Kinetics of isosorbide dinitrate and relationships to pharmacological effects.硝酸异山梨酯的动力学及其与药理作用的关系。
Br J Clin Pharmacol. 1981 Jun;11(6):579-89. doi: 10.1111/j.1365-2125.1981.tb01174.x.
4
[Pharmacokinetics, effect and tolerance of isosorbide dinitrate and isosorbide-5-mononitrate in healthy persons].[硝酸异山梨酯和5-单硝酸异山梨酯在健康人群中的药代动力学、疗效及耐受性]
Med Welt. 1981 Apr 7;32(14A):508-16.
5
Isosorbide dinitrate pharmacokinetics.
Arzneimittelforschung. 1982;32(10):1329-33.
6
Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations.
J Pharm Sci. 1983 May;72(5):496-9. doi: 10.1002/jps.2600720505.
7
Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.异山梨醇二硝酸酯和异山梨醇单硝酸酯在人体中的口服吸收与处置
Arzneimittelforschung. 1983;33(7):980-4.
8
[Pharmacokinetics and metabolism of organic nitrates].
Z Kardiol. 1985;74 Suppl 1:1-7.
9
Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies.人血浆中异山梨醇二硝酸酯快速测定的改进方法及其在药代动力学研究中的应用。
J Chromatogr. 1978 Nov 1;146(3):457-64. doi: 10.1016/s0378-4347(00)81204-9.